Associate Director, University of Hawaii Cancer Center
Dr. Ward is a Member of the National Academy of Sciences and has served on the Advisory Board of several successful biotechnology companies in the area of molecular diagnostics and drug discovery. He is a fellow of the American Association for the Advancement of Science, holds an honorary Doctorate of Science from the Memorial University of New Foundland.
Dr. George F. Vande Woude received his M.S. (1962) and Ph.D. (1964) from Rutgers University. From 1964-1972, he served first as a postdoctoral research associate, then as a research virologist for the US Department of Agriculture at Plum Island Animal Disease Center. In 1972, he joined the National Cancer Institute as Head of the Human Tumor Studies and Virus Tumor Biochemistry Sections. In 1980, he was appointed Chief of the Laboratory of Molecular Oncology and, in 1983, he was selected to be Director of the Advanced Bioscience Laboratories-Basic Research Program at the National Cancer Institute, Frederick, MD, a position he held until 1998. From 1995-1998, Dr. Vande Woude was Special Advisor to the Director of the National Cancer Institute and served to reorganize the intramural basic science at NCI. In 1999, he was selected to be the first Director of the newly created Van Andel Research Institute in Grand Rapids, Michigan, a position he held until February 2009. He is currently a Distinguished Scientific Fellow.
Senior Executive Consultant
David brings 30 years of experience in the biopharmaceutical industry, and has served as:
- Chair of the PhRMA Law Section.
- The global head lawyer at Bristol-Myers Squibb in three different practice areas: Regulatory Law, Transactions and Intellectual Property.
- A member of the BMS Research & Development Executive Committee for over 10 years.
- The leader of multifunctional teams that handled high profile projects in areas such as intellectual property strategy/exclusivity challenges, scientific integrity investigations, complex orphan drug and pediatric research matters, management of the fallout from negative drug safety findings and the reassessment of a major company’s approach to risk and control.
Researchers have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers.
The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers say.